New SSTR2 ligands disclosed in Qianhangjiang Pharmaceutical patent
April 28, 2025
Qianhangjiang Pharmaceutical Co. Ltd. has divulged somatostatin peptide analogues acting as somatostatin receptor type 2 (SSTR2) ligands reported to be useful for the treatment of cancer and acromegaly.